We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Celldex Therapeutics Inc (CLDX) USD0.001

Sell:$52.06 Buy:$52.43 Change: $0.19 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.19 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.19 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Contact details

53 Frontage Road, Suite 220
United States
+1 (908) 2007500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.90 billion
Shares in issue:
55.90 million
United States
US dollar

Key personnel

  • Sam Martin
    Chief Financial Office, Senior Vice President, Secretary
  • Tibor Keler
    Executive Vice President, Chief Scientific Officer
  • Freddy Jimenez
    Senior Vice President, General Counsel
  • Sarah Cavanaugh
    Senior Vice President - Corporate Affairs and Administration
  • Elizabeth Crowley
    Senior Vice President, Chief Product Development Officer
  • Margo Heath-Chiozzi
    Senior Vice President - Regulatory Affairs
  • Ronald Pepin
    Senior Vice President and Chief Business Officer
  • Richard Wright
    Senior Vice President, Chief Commercial Officer
  • Diane Young
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.